Seroprevalence of hepatitis E virus in patients with chronic liver disease

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
ARAUJO, Lilian Rose Maia Gomes de
BATISTA, Andrea Doria
COELHO, Maria Rosangela Cunha Duarte
SANTOS, Joelma Carvalho
CUNHA, Gabriel Galindo
LEAL, Gabriela Rodrigues Aguiar
DOMINGUES, Ana Lucia Coutinho
LOPES, Edmundo Pessoa
Citação
BRAZILIAN JOURNAL OF MICROBIOLOGY, v.55, n.1, p.357-364, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionThe seroprevalence of hepatitis E virus (HEV) in patients with chronic liver disease (CLD) is little known in Brazil. Studies have suggested that HEV may harmfully influence the course of CLD, with a higher risk of progression to cirrhosis.ObjectiveTo estimate the prevalence of the anti-HEV antibody (IgG) in patients with CLD and to describe demographic data and risk factors, as well as clinical-laboratory and ultrasound parameters.Patients and methodsCross-sectional study that included 227 patients with CLD followed at a referral outpatient clinic from June 2022 to March 2023. The patients were investigated clinically and tested for liver functions, anti-HEV IgG and, in positive cases, for HEV-RNA. Ultrasonography of the upper abdomen was also carried out.ResultsInvestigation of 227 patients (50 with hepatitis B, 49 with nonalcoholic fatty liver disease, 33 with hepatitis C, 17 with alcoholic liver disease, 16 with schistosomiasis and 62 with mixed disease), 55.5% were female, with an average age of 57 +/- 13 years; 37.9% had liver cirrhosis. Seven patients (3.08%) presented anti-HEV positive and HEV-RNA negative. Ultrasound identified association between anti-HEV and contact with pigs, presence of gynecomastia or palmar erythema, lower platelet count, higher APRI and FIB-4 values, and splenomegaly.ConclusionAlthough the prevalence of anti-HEV in patients with CLD was low in this study, the antibody was observed more frequently in cases with a history of contact with pigs and with clinical-laboratory or imaging evidence of more advanced chronic liver disease.
Palavras-chave
Hepatitis E virus, Hepatitis E, Seroprevalence, Liver cirrhosis
URI
https://observatorio.fm.usp.br/handle/OPI/59145
Referências
  1. Abravanel F, 2017, EMERG INFECT DIS, V23, P1191, DOI 10.3201/eid2307.170318
  2. Bezerra LA, 2019, ACTA TROP, V189, P65, DOI 10.1016/j.actatropica.2018.09.026
  3. Bricks G, 2019, BRAZ J INFECT DIS, V23, P45, DOI 10.1016/j.bjid.2019.02.002
  4. Buescher G, 2021, LIVER INT, V41, P449, DOI 10.1111/liv.14695
  5. Cunha GG, 2022, BRAZ J MICROBIOL, V53, P1995, DOI 10.1007/s42770-022-00816-z
  6. da Silva CM, 2019, INT J INFECT DIS, V86, P114, DOI 10.1016/j.ijid.2019.06.027
  7. Moraes DFDD, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11082290
  8. de Oliveira EF, 2017, FOOD ENVIRON VIROL, V9, P256, DOI 10.1007/s12560-017-9292-6
  9. Debing Y, 2016, J HEPATOL, V65, P200, DOI 10.1016/j.jhep.2016.02.045
  10. Ferreira AC, 2018, ARCH VIROL, V163, P43, DOI 10.1007/s00705-017-3562-3
  11. Gomes-Gouvêa MS, 2013, HEPATOLOGY, V58, p1052A
  12. Hering T, 2014, J MED VIROL, V86, P948, DOI 10.1002/jmv.23915
  13. Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13
  14. Kamar N, 2012, LANCET, V379, P2477, DOI 10.1016/S0140-6736(11)61849-7
  15. Kamar N, 2011, GASTROENTEROLOGY, V140, P1481, DOI 10.1053/j.gastro.2011.02.050
  16. Li PF, 2020, LIVER INT, V40, P1516, DOI 10.1111/liv.14468
  17. Ma ZR, 2022, J HEPATOL, V77, P1109, DOI 10.1016/j.jhep.2022.05.006
  18. Menezes GBL, 2023, MED RES ARCH, V11, DOI [10.18103/mra.v11i5.3773, DOI 10.18103/MRA.V11I5.3773]
  19. de Oliveira JMNS, 2018, INT J INFECT DIS, V69, P41, DOI 10.1016/j.ijid.2018.01.032
  20. OPAS. Organizacao Pan-americana da Saude, 1997, MET INV EP DOENC TRA, V1
  21. Pandolfi R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176409
  22. Passos AM, 2013, J MED VIROL, V85, P615, DOI 10.1002/jmv.23494
  23. Passos-Castilho AM, 2017, BRAZ J INFECT DIS, V21, P535, DOI 10.1016/j.bjid.2017.05.004
  24. Passos-Castilho AM, 2016, BRAZ J INFECT DIS, V20, P262, DOI 10.1016/j.bjid.2016.03.001
  25. Passos-Castilho AM, 2016, J MED VIROL, V88, P361, DOI 10.1002/jmv.24336
  26. Paternostro R, 2021, HEPATOL RES, V51, P69, DOI 10.1111/hepr.13581
  27. Tengan FM, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-018-0514-4
  28. da Silva SMT, 2012, MEM I OSWALDO CRUZ, V107, P338, DOI 10.1590/S0074-02762012000300007
  29. Wang B, 2021, CURR OPIN MICROBIOL, V59, P8, DOI 10.1016/j.mib.2020.07.004
  30. WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
  31. Wong RJ, 2021, J VIRAL HEPATITIS, V28, P1643, DOI 10.1111/jvh.13597

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC